Cover Image

Concentration–QTc Modeling to Support Clinical Development of Fezolinetant

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Jace C. Nielsen, Masako Saito, Xuegong Wang, Megumi Iwai, Graeme L. Fraser, Steven Ramael, Jiayin Huang
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Clinical Pharmacology in Drug Development
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study
by: Akira Koibuchi, et al.
Published: (2025)

Lack of Concentration‐QTc Relationship and Cardiac Risk With Vatiquinone Therapeutic and Supratherapeutic Doses
by: Lucy Lee, et al.
Published: (2024)

Concentration‐QTc Modeling of the DPP‐4 Inhibitor HSK7653 in a First‐in‐Human Study of Chinese Healthy Volunteers
by: Xiaoxu Wang, et al.
Published: (2024)

In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers
by: Megumi Iwai, et al.
Published: (2024)

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment
by: Megumi Iwai, et al.
Published: (2025)

Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study
by: Borje Darpo, et al.
Published: (2024)

The Work Behind the First Dose: How Early Clinical Studies Shape the Course of Drug Development
by: Amalia M. Issa
Published: (2026)

Correction to “Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsenin Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses”
Published: (2025)

A Randomized Thorough QT Trial Using Concentration‐QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization
by: Osman S. Turkoglu, et al.
Published: (2025)

First‐in‐Human Study of Merotocin, a Short‐Acting Peptidic Oxytocin Receptor Agonist for Lactation Support
by: Yu Bagger, et al.
Published: (2025)

From Reflection to Acceleration: Clinical Pharmacology’s 2025 Lessons and 2026 Opportunities
by: Amalia M. Issa
Published: (2026)

Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity
by: Amalia M. Issa
Published: (2026)

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV
by: Kelong Han, et al.
Published: (2025)

From Bench to Bedside and Beyond: Shaping the Future of Early‐Phase Clinical Pharmacology at CPDD
by: Amalia M. Issa
Published: (2025)

Clinical Study on the Eradication of Helicobacter pylori by Vonoprazan Combined with Amoxicillin for 10‐Day Dual Therapy
by: Kunfeng Yan, et al.
Published: (2024)

A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk
by: Chenna Keshava Reddy Sannala, et al.
Published: (2024)

Optimization of Romiplostim Biosimilar Efficacy Trial Using In Silico Clinical Trial Approach for Patients With Immune Thrombocytopenia
by: Aleksandr Petrov, et al.
Published: (2024)

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants
by: Andrea Francesco Daniele Di Stefano, et al.
Published: (2025)

Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure
by: Ekaterina Koksharova, et al.
Published: (2024)

Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach
by: Michiel de Vries, et al.
Published: (2024)

Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data
by: Sarah A. Buckley, et al.
Published: (2026)

Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants
by: Xiao‐Jian Zhou, et al.
Published: (2025)

Computer‐Aided Algorithmic Approaches to Drug Development for Multi‐Mutant HIV‐1 Reverse Transcriptase
by: Akmal Zubair, et al.
Published: (2025)

Safety and Pharmacokinetics of a Combined Antioxidant Therapy against Myocardial Reperfusion Injury: A Phase 1 Randomized Clinical Trial in Healthy Humans
by: Abraham I.J. Gajardo Cortez, et al.
Published: (2024)

Clinical Significance of IL‐4 and IL‐21 Concurrent Elevation in Predicting Disease Activity Score and Antihistamine Treatment Response in Chronic Spontaneous Urticaria
by: Shining Wang, et al.
Published: (2026)

New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy Subjects
by: Sigrid Balser, et al.
Published: (2024)

Bioequivalence and Safety Assessment of 2 Formulations of Low‐Dose Metformin Hydrochloride under Fasting Conditions in Healthy Chinese Participants: A Randomized Phase 1 Clinical Trial
by: Ming‐Li Sun, et al.
Published: (2024)

Comparative Pharmacokinetics and Bioequivalence of 2 Formulations of Bosentan Dispersible Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions
by: Zhaoming Huang, et al.
Published: (2025)

A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer
by: Michael J. Hanley, et al.
Published: (2025)

Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
by: Mary P. Choules, et al.
Published: (2025)

Bioequivalence Analysis of Clindamycin Hydrochloride Capsules in Healthy Chinese Subjects Under Fasted and Fed Conditions
by: Zhi Wang, et al.
Published: (2024)

Extrapolation of Midazolam Disposition in Neonates Using Physiological‐Based Pharmacokinetic/Pharmacodynamic Modeling
by: Tangping Zhao, et al.
Published: (2025)

Population Pharmacokinetics of Butylphthalide Injection in Elderly Chinese Patients With Ischemic Stroke
by: Shu‐Xian Lyu, et al.
Published: (2025)

Population Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim Biosimilar GP40141 and Reference Product in Healthy Volunteers to Evaluate Biosimilarity
by: Igor Makarenko, et al.
Published: (2024)

Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
by: Shintaro Nakayama, et al.
Published: (2024)

Evaluation of Acarbose Bioequivalence in Healthy Chinese Populations Using Novel Pharmacodynamic End Points
by: Linling Que, et al.
Published: (2024)

Pharmacokinetics, Bioequivalence, and Safety of Levothyroxine Sodium Tablets in Healthy Chinese Subjects
by: Juan Jin, et al.
Published: (2025)

Target‐Mediated Modeling of Alirocumab in Adolescents and Children ≥8 to <12 Years of Age Using Phase II and III Data
by: Pavel Kovalenko, et al.
Published: (2025)

Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients With Metastatic Castration‐Resistant Prostate Cancer
by: Yixian Liu, et al.
Published: (2024)

Bioequivalence Study of Atenolol Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions
by: Yongtao Li, et al.
Published: (2024)